Novozymes A/S Stock

Novozymes A/S Liabilities

The The Liabilities of Novozymes A/S (NSIS B.CO) as of Aug 13, 2026 is 4.02 B EUR. In the previous year, The Liabilities was 1.93 B EUR — a change of 108.23% (higher).

Liabilities

4.02 BEUR

YoY

108.23%

Last updated:

In 2026, Novozymes A/S's total liabilities amounted to 4.02 B EUR, a 108.23% difference from the 1.93 B EUR total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Novozymes A/S Stock analysis

What does Novozymes A/S do? Novozymes A/S is a leading company in the field of biocatalysis and microbial solutions. It was founded in Denmark in 1925 under the name Nordisk Insulinlaboratorium. In 2000, the company was renamed Novozymes A/S and became part of the globally operating Novo Group. Novozymes' business model is to optimize the use of biocatalysts, enzymes, and microorganisms to offer sustainable solutions for various industries. Biocatalysts are biological molecules that accelerate or enable chemical reactions. The company works closely with customers in agriculture, household, food and beverage, laundry and cleaning products, animal feed, bioenergy, and biopharmaceutical industries. Novozymes' offerings include various divisions. The largest is the enzymes division, which produces enzymes for various industries. Novozymes' enzymes are used in the food and beverage industry, pulp and paper industry, and bioenergy, among others. The microbial solutions division offers various microorganisms that can be used in the production of biogas, animal feed, or odor removal. Novozymes also has a bioagriculture division that develops solutions for sustainable agriculture. This includes disease- and pest-resistant bioseeds, as well as enhanced soil and plant care. The company also has a biopharmaceutical division that focuses on producing enzymes for disease treatment. An important goal of Novozymes is to promote sustainability and environmental protection. The company advocates for the use of renewable resources and energy-efficient processes. This is also reflected in their products, which contribute to optimizing agricultural processes and reducing greenhouse gas emissions, for example. One example of a Novozymes product is NovoGro, a biofertilizer for sustainable agriculture. NovoGro enhances nutrient uptake in plants and contributes to healthy soils. Another product is an enzyme blend called Novozyme 188, which is used in beer production to improve filtration. In summary, Novozymes A/S is a company specializing in biocatalysis and microbial solutions. The company works closely with customers from various industries to offer sustainable solutions and promote environmental protection. Novozymes has different divisions and offers solutions such as enzymes and microorganisms that can be used in the food and beverage industry, pulp and paper industry, bioenergy, biopharmaceuticals, and many other areas. With its commitment to sustainability and environmental protection, Novozymes contributes to shaping a better future. Novozymes A/S is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Novozymes A/S's Liabilities

Novozymes A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Novozymes A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Novozymes A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Novozymes A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Novozymes A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Novozymes A/S stock

The Liabilities of Novozymes A/S is 4.02 B EUR in 2026.

The Liabilities of Novozymes A/S changed from 1.93 B EUR to 4.02 B EUR, representing a 108.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Novozymes A/S since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Novozymes A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Novozymes A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Novozymes A/S